Testosterone Replacement Therapy (TRT)

What it is

Testosterone replacement therapy (TRT) is the medical treatment for men diagnosed with hypogonadism, a condition where the testes produce insufficient testosterone. This is not performance enhancement or steroid abuse. TRT aims to restore testosterone levels to normal physiological ranges in men whose bodies cannot produce adequate amounts naturally.

Primary hypogonadism occurs when the testes themselves malfunction, while secondary hypogonadism results from problems with the pituitary gland or hypothalamus. Most men are diagnosed when blood tests show total testosterone below 300 ng/dL (10.4 nmol/L), though some physicians use 350 ng/dL as a cutoff, combined with symptoms of low testosterone.

Common symptoms include decreased libido, erectile dysfunction, fatigue, loss of muscle mass, increased body fat, mood changes, and reduced bone density. TRT has been studied and prescribed since the 1940s, with modern formulations providing safer and more convenient treatment options than earlier preparations. The goal is symptom relief and prevention of long-term health consequences associated with testosterone deficiency.

How it works

Exogenous testosterone replaces what the body fails to produce naturally. Once injected, testosterone circulates through the bloodstream and binds to androgen receptors throughout the body. These receptors are found in muscle, bone, fat tissue, brain, heart, liver, and reproductive organs, explaining testosterone's wide-ranging effects on male physiology.

In muscle tissue, testosterone promotes protein synthesis and muscle fiber growth while reducing protein breakdown. In bone tissue, it stimulates osteoblast activity to maintain bone mineral density. In the brain, testosterone affects mood, cognition, energy levels, and libido through its actions on neurotransmitter systems and neural pathways.

The most commonly prescribed forms are testosterone cypionate and enanthate, both long-acting esters that extend the hormone's half-life. Cypionate has an 8-day half-life while enanthate lasts approximately 4.5 days. Testosterone propionate is shorter-acting with a 2-day half-life but requires more frequent injections. These esters are cleaved by enzymes in the body to release free testosterone.

Some testosterone converts to estradiol through the aromatase enzyme, particularly in fat tissue. This conversion is normal and necessary for bone health, brain function, and cardiovascular protection. However, excessive aromatization can cause side effects. Additionally, some testosterone converts to dihydrotestosterone (DHT) via 5-alpha reductase, which affects prostate, hair follicles, and skin.

What the research shows

The T-Trial (Testosterone Trials), a comprehensive study of 790 men aged 65 and older with testosterone levels below 275 ng/dL, demonstrated significant improvements in sexual function, mood, and physical performance with testosterone therapy. Men receiving testosterone gel showed improved sexual activity, desire, and erectile function compared to placebo over 12 months (Snyder et al., New England Journal of Medicine, 2016. PMID: 26840133).

A systematic review and meta-analysis of 59 studies involving 5,464 men found that testosterone therapy significantly increased lean body mass by an average of 1.6 kg and decreased fat mass by 1.6 kg compared to placebo. Muscle strength improvements were most pronounced in men with baseline testosterone below 300 ng/dL (Corona et al., Clinical Endocrinology, 2016. PMID: 26843175).

Cardiovascular effects remain complex and somewhat controversial. The TRAVERSE trial, the largest cardiovascular safety study of testosterone therapy, followed 5,246 men for a median of 22 months. Results showed no increased risk of major cardiovascular events compared to placebo, with a hazard ratio of 0.96 (Lincoff et al., New England Journal of Medicine, 2023. PMID: 37486794). However, some studies suggest potential benefits including improved insulin sensitivity and reduced inflammation markers.

Bone density studies consistently show positive effects. A meta-analysis of 27 trials found testosterone therapy increased lumbar spine bone mineral density by 3.7% and total hip density by 2.5% over 12-36 months (Fernandez-Balsells et al., Journal of Clinical Endocrinology & Metabolism, 2010. PMID: 20061435). These improvements reduce fracture risk in older men with testosterone deficiency. However, hematocrit elevation occurs in 15-20% of patients and requires monitoring.

Typical protocol

Standard TRT typically starts with testosterone cypionate 100-200 mg per week via intramuscular or subcutaneous injection. Most physicians begin with 100-150 mg weekly and adjust based on symptom response and blood levels measured 6-8 weeks after starting or changing doses. The goal is to achieve total testosterone levels in the upper normal range (600-1000 ng/dL).

Injection frequency significantly impacts effectiveness and side effects. Traditional weekly injections create peaks and valleys in testosterone levels, potentially causing mood swings and increased estrogen conversion. Many patients achieve better results with twice-weekly dosing (50-100 mg every 3.5 days) or even daily microdoses (15-30 mg daily). More frequent injections provide more stable blood levels.

Subcutaneous injection has gained popularity over intramuscular administration. SubQ injections use smaller needles (27-30 gauge), cause less tissue trauma, and may produce more stable levels. Studies show equivalent effectiveness between IM and SubQ routes. Injection sites should rotate between abdomen, thighs, and deltoids to prevent scar tissue buildup.

Regular blood monitoring is essential for safe TRT. Initial labs include total testosterone, free testosterone, estradiol, complete blood count (for hematocrit), comprehensive metabolic panel, and PSA. Monitoring occurs at 6 weeks, 3 months, 6 months, then annually if stable. Hematocrit should remain below 50-52%, and estradiol typically ranges from 20-40 pg/mL. Use our peptide calculator for reconstitution math if using compounded formulations.

Side effects and risks

Estrogen-related side effects are among the most common TRT complications. When testosterone converts to estradiol via aromatase, elevated estrogen can cause water retention, gynecomastia (breast tissue growth), mood swings, and reduced libido despite normal testosterone levels. This occurs more frequently with higher doses and less frequent injections. Some patients require aromatase inhibitors or estrogen-blocking supplements.

Hematocrit elevation affects 15-20% of TRT patients as testosterone stimulates red blood cell production. Levels above 50-52% increase stroke and heart attack risk due to blood thickening. Regular blood donations, dose reduction, or temporary discontinuation may be necessary. Sleep apnea can worsen on TRT, particularly in overweight men, potentially requiring CPAP therapy.

Testicular atrophy occurs in virtually all TRT patients as exogenous testosterone suppresses luteinizing hormone (LH) and follicle-stimulating hormone (FSH) production. Testicles shrink by 10-25% within 3-6 months. Fertility suppression is also common as sperm production decreases significantly. Men planning to father children should consider fertility preservation or alternative treatments like clomiphene or HCG.

Hair loss acceleration can occur in genetically predisposed men as testosterone converts to DHT, which attacks hair follicles. Acne may worsen, particularly on the back and shoulders. Prostate enlargement (BPH) may progress faster on TRT, though testosterone does not cause prostate cancer. Regular PSA monitoring and digital rectal exams are recommended. Mood changes can include increased aggression or irritability, particularly if estrogen levels become imbalanced.

Related compounds